{"id":1008869,"date":"2026-10-09T07:42:58","date_gmt":"2026-10-09T11:42:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/"},"modified":"2026-10-09T07:42:58","modified_gmt":"2026-10-09T11:42:58","slug":"alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/","title":{"rendered":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and SAN FRANCISCO, Oct.  09, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sY5HMqpmeS6lWPjPIiIIungwyikOku5qqR01VxxIVYh8KfgLpIt6W2LY5uMyeDiKCP9Q6olTAN8WBVNTFl6FnLWzqqdMEhp2Mp5ofIAF1qI=\" rel=\"nofollow\" target=\"_blank\">Alterity Therapeutics<\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia.<\/p>\n<p align=\"justify\">At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors.<\/p>\n<p align=\"justify\">\n        <strong>About Alterity Therapeutics Limited\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company\u2019s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RekghNEL_Zx99-WHnMAX-JgK6zxaZOu3t80qqBKAZcnCk2ngTuL4RL8Uv-5HmXY7LqJMCPwFppZZVNZRQn0_OVy7YUzPoaXoq6qzGNSwGMw=\" rel=\"nofollow\" target=\"_blank\">https:\/\/alteritytx.com<\/a>.<\/p>\n<p>\n        <strong>Authorisation &amp; Additional information<\/strong><br \/>\n        <br \/>This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Elyse Shapiro<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rZXdmy41TOaCUAQ3asKYtQtdQggBSOIMXzX36zMnzjhO7QpUBy3YM72Of2VsexT_XA4KpLIDsw404bGQL-kBSG4VAJQgv0pHwjcX50UwTEA=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><\/p>\n<p>Remy Bernarda<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rZXdmy41TOaCUAQ3asKYtQb4ySGQok1vQRa5lJQUhrxsH7kj7AZu_dwOQwOjsVh3KEbJGJ6lalC1Vx83HTuydstQBuvWnhjJNMsmzXgHLJI=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><br \/>+1 (415) 203-6386<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Melissa Tempra<br \/>NWR Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7pg_2f7P7wgq67w5--lpdxJIrmke-582U9EcNZWQRC1w9XBVyA-R9N8X2XHK440729ja2-iAnt-7hHrmx_DlK8YZTRk2a6-PLBUiWgZNR1Tjrfoem8-4gklIPzaIBrHVlh0VCtSP2zC49lCY4YcJzA==\" rel=\"nofollow\" target=\"_blank\">melissa@nwrcommunications.com.au<\/a><\/p>\n<p>Casey McDonald<br \/>Tiberend Strategic Advisors, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LuaopxglqDxiuH6rna1Wf7qIPUiodb5kYO5jj8B4BoHo1J3RoTKNuTIwkzPvbSvfkXxYzuSksdWOMEIuWcE6nt3LmXVVJe1WMMWxzrGLHZw=\" rel=\"nofollow\" target=\"_blank\">cmcdonald@tiberend.com<\/a><br \/>+1 (646) 577-8520<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2I5MzZmM2EtNjUxNS00MzMwLWEyMjAtYThkNTcyMTFlNjZmLTEyNjgyNjItMjAyNi0xMC0wOS1lbg==\/tiny\/ALTERITY-THERAPEUTICS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors. About Alterity Therapeutics Limited\u00a0 Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0&#8220;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1008869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors. About Alterity Therapeutics Limited\u00a0 Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. &hellip; Continue reading &quot;Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T11:42:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0\",\"datePublished\":\"2026-10-09T11:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/\"},\"wordCount\":285,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/\",\"name\":\"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\",\"datePublished\":\"2026-10-09T11:42:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk","og_description":"MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a corporate presentation and will also host roundtable discussions with investors. About Alterity Therapeutics Limited\u00a0 Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. &hellip; Continue reading \"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-09T11:42:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0","datePublished":"2026-10-09T11:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/"},"wordCount":285,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/","name":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=","datePublished":"2026-10-09T11:42:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MjYzOSM3ODg3Mjc0IzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-canaccord-genuity-drug-and-device-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1008869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1008869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1008869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1008869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}